CTOs on the Move


 
Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company based in Roseville, Minnesota. Our mission is to address health challenges such as obesity, diabetes, high cholesterol and food allergies by developing healthier food ingredients that produce high-quality, convenient and delicious food, while also providing agriculturally advantageous crop traits to farmers. As a leader in our field, our team is positively changing the way Americans eat by pioneering a paradigm shift to help make the food you love a healthier choice™.
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.calyxt.com
  • 2800 Mount Ridge Road
    Roseville, MN USA 55112
  • Phone: 651.683.2807

Executives

Name Title Contact Details
Vijay Gullapalli
Vice President of Artificial Intelligence, Machine Learning and Data Science Profile
Paul Weier
Director Of Information Technology Profile
Travis Frey
Chief Technology Officer Profile

Funding

Calyxt raised $60.9M on 05/22/2018

Similar Companies

Lipomics Technologies

Lipomics Technologies is a West Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chi Botanic

Changing how we grow with plant cell cultures.

Pharmaceutical Product Development

PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments.

IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.

Passage Bio

Passage Bio was launched with the vision to be a first in class fully-integrated biotech company developing life transforming AAV-delivered in vivo therapeutics for the treatment of rare CNS diseases. In collaboration with the University of Pennsylvania Gene Therapy Program, Philadelphia-based Passage Bio plans to advance a portfolio of 5 rare disease indications in the neuro/CNS genetic space through IND-enabling studies using best-in-class AAV technology and know-how. Subsequently, Passage Bio will be responsible for all clinical development and will collaborate with Penn`s Orphan Disease Center to support these efforts.